Community-acquired pneumonia: aetiology, antibiotic resistance and prospects of phage therapy.

J Chemother

Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, Bangladesh.

Published: December 2020

Bacteria are the most common aetiological agents of community-acquired pneumonia (CAP) and use a variety of mechanisms to evade the host immune system. With the emerging antibiotic resistance, CAP-causing bacteria have now become resistant to most antibiotics. Consequently, significant morbimortality is attributed to CAP despite their varying rates depending on the clinical setting in which the patients being treated. Therefore, there is a pressing need for a safe and effective alternative or supplement to conventional antibiotics. Bacteriophages could be a ray of hope as they are specific in killing their host bacteria. Several bacteriophages had been identified that can efficiently parasitize bacteria related to CAP infection and have shown a promising protective effect. Thus, bacteriophages have shown immense possibilities against CAP inflicted by multidrug-resistant bacteria. This review provides an overview of common antibiotic-resistant CAP bacteria with a comprehensive summarization of the promising bacteriophage candidates for prospective phage therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1080/1120009X.2020.1807231DOI Listing

Publication Analysis

Top Keywords

community-acquired pneumonia
8
antibiotic resistance
8
phage therapy
8
bacteria
6
cap
5
pneumonia aetiology
4
aetiology antibiotic
4
resistance prospects
4
prospects phage
4
therapy bacteria
4

Similar Publications

Introduction: (), a common pathogen of community-acquired pneumonia in school-age children and adolescents, can cause epidemics worldwide. In late 2023, the incidence of infection among children reached a high level.

Methods: We investigated the antimicrobial susceptibility of 62 isolates obtained from children with pneumonia in Beijing between 2021 and 2023, and analyzed the correlation of antimicrobial susceptibility with molecular characteristics of isolates and clinical manifestations of patients.

View Article and Find Full Text PDF

Effused and Confused: A Case of Severe Adenovirus Pneumonia in a Teen.

Cureus

December 2024

Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, University General Hospital of Larissa, Larissa, GRC.

Adenovirus is a common pathogen responsible for respiratory infections, including pneumonia, predominantly in pediatric populations but also in immunocompromised adults. This case report details an 18-year-old immunocompetent male presenting with severe lobar pneumonia and pleural effusion, initially suggesting a bacterial origin. Despite antibiotic treatment, the patient's symptoms persisted, prompting further investigation.

View Article and Find Full Text PDF

The role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia.

Antimicrob Steward Healthc Epidemiol

December 2024

Division of Infectious Diseases, Veteran's Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.

A β-lactam plus a macrolide or a respiratory fluoroquinolone alone is recommended as standard empiric antibacterial therapy for non-severe adults hospitalized with community-acquired pneumonia (CAP) per Infectious Diseases Society of America guidelines. However, the evidence in support of adding empiric atypical antibacterial therapy, and specifically the addition of a macrolide, is conflicting and should be balanced with additional factors: the necessity of covering atypical organisms, benefits of macrolide-associated immunomodulation, harms associated with antibiotic use, and selection for antibiotic-resistant organisms. In this review, we examine the role of atypical coverage in standard treatment regimens for patients admitted with non-severe CAP and specifically focus on the addition of macrolides to β-lactams.

View Article and Find Full Text PDF

Background: Serotype-specific urinary antigen detection (UAD) assay results can be used to estimate the serotype contribution among adults with pneumococcal community-acquired pneumonia (CAP) and to guide recommendations regarding higher-valency pneumococcal conjugate vaccines (PCVs).

Methods: Adults aged ≥18 years hospitalized with radiographic evidence of CAP were prospectively enrolled in 4 US cities from November 2019 to December 2020, overlapping the coronavirus disease 2019 (COVID-19) pandemic. Data were collected by patient interview and medical chart review.

View Article and Find Full Text PDF

Objective Community-acquired pneumonia is an acute infectious disease with potentialy life-threatening consequences. Because invasive mechanical ventilation (IMV) requires the attention of many medical staff, early risk prediction at the time of admission is expected to lead to a predictable course of patient care and the appropriate allocation of medical resources. There are a limited number of reports on predictive factors for IMV, such as SMART-COP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!